



# Basics of Platelet-Rich Fibrin Therapy

*Richard J. Miron, DDS, MSc, PhD; Mark Bishara, DDS; and Joseph Choukroun, MD*

**Upon successful completion of this CE activity, 2 CE credit hours may be awarded.**

**A Peer-Reviewed CE Activity by**



**DENTISTRY TODAY**  
is an ADA CERP Recognized Provider

**ADA CERP**® | Continuing Education  
Recognition Program

Dentistry Today, Inc. is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry. Concerns or complaints about a CE provider may be directed to the provider or to ADA CERP at [ada.org/goto/cerp](http://ada.org/goto/cerp).



Approved PACE Program  
Provider FAGD/MAGD Credit  
Approval does not imply  
acceptance by a state or  
provincial board of dentistry  
or AGD endorsement.  
June 1, 2015 to May 31,  
2018 AGD PACE approval  
number: 309062

Opinions expressed by CE authors are their own and may not reflect those of *Dentistry Today*. Mention of specific product names does not infer endorsement by *Dentistry Today*. Information contained in CE articles and courses is not a substitute for sound clinical judgment and accepted standards of care. Participants are urged to contact their state dental boards for continuing education requirements.

# Basics of Platelet-Rich Fibrin Therapy

Effective Date: 04/01/2017 Expiration Date: 04/01/2020

**Learning Objectives:** After reading this article the individual will learn: (1) the history and current status of platelet-rich fibrin (PRF), and (2) clinical uses for PRF in dentistry.

## About the Authors



**Dr. Miron** is an adjunct faculty member of the department of periodontology at Nova Southeastern University in Fort Lauderdale, Fla. He is the lead investigator in the Miron Lab ([themironlab.com](http://themironlab.com)) and the head educator at Advanced PRF Education ([prfedu.com](http://prfedu.com)). He completed a masters in cell biology at the University of Western Ontario (Canada), a PhD in molecular and cell biology at the University of Bern (Switzerland), and a DDS degree at the University of Laval (Canada). He has performed numerous short-stay postdoctoral research fellowships at the University of Wuhan (China) and mentors research scholars. His research interests

involve enamel matrix proteins for bone and periodontal regeneration, bioactive growth factors, platelet-rich fibrin (PRF), osteoinductive bone grafting materials, and guided bone regeneration in implant dentistry. He is the recipient of many international young investigators awards and has authored more than 100 peer-reviewed research articles in dental and biomaterial journals. He can be reached via email at [rmiron@nova.edu](mailto:rmiron@nova.edu).

*Disclosure: Dr. Miron reports no disclosures.*

**Dr. Bishara** has a practice focused on but not limited to implants, bone grafting material regeneration, and tissue regeneration in Bowmanville, ON, Canada. He is an active member of the International Association of Dental Research and collaborates with members of the Miron Lab, with a focus on tissue regeneration utilizing PRF. He can be reached at [bbishara6@gmail.com](mailto:bbishara6@gmail.com).

*Disclosure: Dr. Bishara reports no disclosures.*

**Dr. Choukroun** is both a trained anesthesiologist and pain management specialist. His research findings led to the development of PRF, which pioneered the field more than 15 years ago as autologous platelet concentrates that could be utilized without anticoagulants. He is currently the president of Syfac, which holds one of the world's largest congresses on growth factors and platelet concentrates. He works as chief of staff in his Pain Therapy Center in Nice, France, and lectures internationally on PRF. He can be reached at [joseph@a-prf.com](mailto:joseph@a-prf.com).

*Disclosure: Dr. Choukroun is a shareholder of the process of PRF.*

**W**ound healing is a complex biological process with 4 overlapping phases including hemostasis, inflammation, proliferation, and remodeling.<sup>1-3</sup> One of the key players during these phases has been the accumulation of platelets, cells that have been shown to be important regulators of hemostasis through vascular and fibrin clot formation.<sup>4</sup> It was proposed in the 1990s that platelet concentrates could be utilized and centrifuged to reach supraphysiological doses to achieve wound healing and tissue regeneration by facilitating angiogenesis. During the past decade, many advancements have been made with respect to the development of a *platelet-rich fibrin* (PRF). This article discusses how further advancements in PRF therapy have provided optimal wound healing at low cost in various indications in regenerative dentistry.

## BRIEF HISTORY OF PLATELET CONCENTRATES

Recently, the use of platelet concentrates has gained tremendous momentum as a regenerative autologous source of growth factors utilized in various fields of medicine. It was originally proposed that concentrated platelets derived from autologous sources could be collected in plasma solutions later to be utilized in surgical sites with the potential to release 6 to 8 times supraphysiological doses of growth factors responsible for promoting local healing.<sup>5,6</sup> Further work by Jameson<sup>7</sup> and Marx<sup>8</sup> led to the popular working name *platelet-rich plasma* (PRP). The goal of PRP was to collect the largest and highest quantities of growth factors from platelets to be later utilized for regenerative purposes. The PRP protocol required more than 30 minutes of centrifugation cycles and the use of anticoagulants to prevent clotting. The final composition of PRP contains more than 95% platelets, known cells responsible for the active secretion of growth factors involved in initiating wound healing of various cell types including osteoblasts, epithelial cells, and connective tissue cells.<sup>7,8</sup>

One of the reported limitations to the PRP technique, apart from its longer centrifugation protocols, was the fact that it included the additional use of bovine thrombin or calcium chloride (CaCl<sub>2</sub>) in addition to coagulation factors. These drastically reduce the healing process during the regenerative phase by preventing coagulation and fibrin clot formation. The entire protocol was technique sensitive, with several phases lasting sometimes upwards of one hour, making it inefficient for everyday dental practice. These limitations later led to the emergence of a second generation of platelet concentrates that takes advantage of the fact that without anticoagulants, a fibrin matrix that incorporates the full set of growth factors trapped within its matrix and slowly released throughout time could be achieved.<sup>9</sup>

# Basics of Platelet-Rich Fibrin Therapy


## From PRP to PRF

Research pioneered by Dr. Joseph Choukroun in the early 2000s led to the development of a second-generation platelet concentrate without utilizing anticoagulation factors. A platelet concentrate lacking coagulation factors could be harvested from the upper layer of centrifugation tubes following single centrifugation cycles of 12 minutes at 2,700 rpm (750 g). This formulation was termed *PRF*, owing to the fact that it contained a fibrin matrix following centrifugation. PRF (leukocyte-PRF, or L-PRF) additionally contains white blood cells (WBCs), the necessary cells involved in the wound healing process by improving defense immunity and secreting a large quantity of growth factors. As depicted in **Figure 1**, macrophages and leukocytes are among the 3 key cell types found in PRF derived from the myeloid lineage (WBCs) and secrete a wide range of growth factors including transforming growth factor-beta, platelet-derived growth factor, and vascular endothelial growth factor. These cells, in combination with neutrophils and platelets, are the main players in tissue wound healing and together are able to further enhance new blood vessel formation (angiogenesis), which subsequently leads to new bone and tissue formation.<sup>10</sup>


The following 3 components are essential to improve tissue repair: (1) a 3-D matrix capable of supporting tissue ingrowth; (2) locally harvested cells capable of influencing tissue growth; and (3) bioactive growth factors capable of enhancing cell recruitment and differentiation within the biomaterial surface. With respect to PRF, all 3 of these properties are met whereby (1) fibrin serves as the scaffold surface material; (2) cells including leukocytes, macrophages, neutrophils, and platelets attract and recruit future regenerative cells to the defect sites; and (3) fibrin serves as a reservoir of growth factors that may be released during 10 to 14 days.<sup>11</sup>

## PRF: A Natural Fibrin Matrix and Its Biological Properties

While PRF was first developed by Choukroun et al in 2001,<sup>12</sup> the lack of an anticoagulant meant that the fibrin clot begins to form during the centrifugation process. When centrifugation tubes are removed, a fibrin clot can be observed in the upper layer of tubes as depicted in **Figure 2**. This technology requires a centrifuge and a collection system present within the office, and since anticoagulants are not utilized, clotting forms rapidly. Therefore, centrifugation must take place within seconds after blood harvesting. The original PRF protocol was first established



**Figure 1.** Natural components of platelet-rich fibrin (PRF) include **(1)** cell types: platelets, leukocytes, and red blood cells; **(2)** a provisional extracellular matrix 3-D scaffold fabricated from autologous fibrin, including fibronectin and vitronectin; **(3)** a wide array of more than 100 bioactive molecules, including most notably platelet-derived growth factor (PDGF), vascular endothelial GF (VEGF), insulin-like GF (IGF), epidermal GF (EGF), transforming growth factor-beta (TGF-β), and bone morphogenetic protein-2 (BMP2). (Reprinted with permission from Miron et al, 2016.)



**Figure 2.** Fibrin clot in the tube after centrifugation.

with a very simple technique: a blood sample was taken without anticoagulant in 10-mL tubes that was immediately centrifuged at 750 g for 12 minutes. The absence of anticoagulant implies the activation in a few minutes of most platelets of the blood sample in contact with the tube walls and the release of the coagulation cascades. Fibrinogen is initially concentrated in the upper layer of the tube, before the circulating thrombin transforms it into fibrin. A fibrin clot is then obtained in the middle of the tube, just between the red corpuscles at the bottom of the tube and the acellular plasma at the top (platelet-poor plasma).




## Basics of Platelet-Rich Fibrin Therapy

Without anticoagulants, the blood samples start to coagulate almost immediately upon contact with the tube glass, and it takes a minimum of a few minutes of centrifugation to concentrate fibrinogen in the middle and upper part of the tube. Quick handling is the only way to obtain a clinically usable PRF matrix. If the duration required to collect blood and launch centrifugation is overly long, failure will occur. By driving out the fluids trapped in the fibrin matrix, practitioners will obtain very resistant autologous fibrin membranes.

### Advanced Platelet Rich Fibrin (A-PRF)


The impact of WBCs on vascularization and bone formation led to modifications in the centrifugation speeds and times, due to the excessively high g-force. Due to high spin cycles, the protocols were modified accordingly to prevent cell loss within the PRF matrix. These new cycles, termed *A-PRF*, reduce the rpm to 1,300 for 8 minutes to maintain a higher amount of WBCs in the fibrin matrix and special glass tubes that are designed to induce a more rapid clotting. After the centrifugation, the tubes are removed and placed in their holders and left for 5 minutes to induce fibrin clot formation. This new fibrin clot is richer in WBCs, and recent research by the authors' group has shown that a higher release of growth factors from A-PRF also improves collagen matrix synthesis and recruitment of progenitor cells.<sup>13</sup>



**Figure 3.** The newer formulation of injectable PRF (i-PRF) is a liquid formulation of PRF found in the top one-mL layer of centrifugation tubes following a 700-rpm spin for 3 minutes. This liquid can be collected in a syringe and reinjected into defect sites or mixed with biomaterials to improve their bioactive properties.

### Injectable Platelet Rich Fibrin (i-PRF)

With the same concept of non-additive platelet derivatives, i-PRF was developed to fulfill the goal of acting as a regenerative agent that could be delivered in liquid formulation by drawing blood rapidly in a specific centrifugation tube at a very low speed of 700 rpm (60 g) for a short centrifugation time (3 minutes). The objective was




**Figure 4.** PRF clots formed to either make membranes or PRF plugs.



**Figure 5.** One of the main uses of PRF has been for the management of extraction socket healing. This is a demonstration of an extraction socket filled with multiple PRF plugs utilized alone. After 3 months of healing, substantial bone regeneration is observed without use of a bone grafting material.

# Basics of Platelet-Rich Fibrin Therapy



**Figure 6.** (a to c) Lateral window sinus augmentation procedures performed by Dr. Alain Simonpieri (Marseille, France) utilizing PRF alone. (d) Notice the bone gain occurring after a 6-month healing period utilizing PRF.

to centrifuge without anticoagulants or additives (Figure 3). This new formulation can be utilized for a variety of procedures including mixing with bone grafts to form a stable fibrin bone graft for improved handling after a short period of time (one to 2 minutes), which improves graft stability. This takes full advantage of the low-speed centrifugation concept and additionally improves wound healing when combined with bone biomaterials.


## Clinical Use of PRF and Indications

In terms of soft-tissue management and maturation, PRF is able to support the development of angiogenesis, immunity, and epithelial coverage. Fibrin has been shown to act as the natural scaffold guiding angiogenesis, which consists of the formation of new blood vessels inside the wound.

Regarding the clinical use of PRF in daily dental practice, PRF may be utilized as a tissue matrix/scaffold (provisional extracellular matrix) with the ability to simultaneously release growth factors during a 10-day period. The clots are prepared in a PRF metallic box, which allows the slight compression of the clots into membranes or plugs to be later utilized as depicted in Figure 4. These can be utilized for a variety of clinical procedures including acting as autologous barrier membranes, extraction socket healing (Figure 5), sinus lifting procedures (Figure 6), implant dentistry, and for the treatment of intrabony defects and gingival recessions (Figure 7), amongst others. Research is continuously ongoing in this field, and patient satisfaction has been considered high due to the use of regenerative materials from autologous sources (patient's own blood).

## CONCLUSION

The use of PRF in regenerative medicine has now seen a huge increase in its use across many fields of medicine due to its ease of use and low costs while providing a completely autologous source of growth factor delivery. Recent modifications to the centrifugation speeds and times (A-PRF) further enhance its regenerative potential and bring to clinical practice a liquid formulation that is injectable during use (i-PRF). Future strategies are continuously being developed to further improve the clinical outcomes following regenerative procedures utilizing platelet concentrates. ♦



**Figure 7.** Use of PRF alone for the treatment of gingival recessions. Notice the soft-tissue wound healing observed. Due to the use of the blood-derived collection of growth factors, PRF alone can be utilized for the regeneration of simple gingival recessions.

## References

- Gosain A, DiPietro LA. Aging and wound healing. *World J Surg.* 2004;28:321-326.
- Eming SA, Brachvogel B, Odorisio T, et al. Regulation of angiogenesis: wound healing as a model. *Prog Histochem Cytochem.* 2007;42:115-170.
- Eming SA, Kaufmann J, Löhner R, et al. Chronic wounds. Novel approaches in research and therapy [in German]. *Hautarzt.* 2007;58:939-944.
- Guo S, DiPietro LA. Factors affecting wound healing. *J Dent Res.* 2010;89:219-229.
- Anfosso G, Trovati M, Mularoni E, et al. Influence of propranolol on platelet aggregation and thromboxane B2 production from platelet-rich plasma and whole blood. *Prostaglandins Leukot Essent Fatty Acids.* 1989;36:1-7.
- Fijnheer R, Pietersz RN, de Korte D, et al. Platelet activation during preparation of platelet concentrates: a comparison of the platelet-rich plasma and the buffy coat methods. *Transfusion.* 1990;30:634-638.
- Jameson CA. Autologous platelet concentrate for the production of platelet gel. *Lab Med.* 2007;38:39-42.
- Marx RE. Platelet-rich plasma: evidence to support its use. *J Oral Maxillofac Surg.* 2004;62:489-496.
- Dohan Ehrenfest DM, Del Corso M, Diss A, et al. Three-dimensional architecture and cell composition of a Choukroun's platelet-rich fibrin clot and membrane. *J Periodontol.* 2010;81:546-555.
- Miron RJ, Fujioka-Kobayashi M, Bishara M, et al. Platelet-rich fibrin and soft tissue wound healing: a systematic review. *Tissue Eng Part B Rev.* 2016 Oct 10. [Epub ahead of print]
- Kobayashi E, Flückiger L, Fujioka-Kobayashi M, et al. Comparative release of growth factors from PRP, PRF, and advanced-PRF. *Clin Oral Investig.* 2016;20:2353-2360.
- Choukroun J, Adda F, Schoeffler C, et al. Une opportunité en paro-implantologie: le PRF. *Implantodontie.* 2001;42:55-62.
- Fujioka-Kobayashi M, Miron RJ, Hernandez M, et al. Optimized platelet-rich fibrin with the low-speed concept: growth factor release, biocompatibility, and cellular response. *J Periodontol.* 2017;88:112-121.

# Basics of Platelet-Rich Fibrin Therapy

## POST EXAMINATION INFORMATION

To receive continuing education credit for participation in this educational activity you must complete the program post examination and receive a score of 70% or better.

### Traditional Completion Option:

You may fax or mail your answers with payment to Dentistry Today (see Traditional Completion Information on following page). All information requested must be provided in order to process the program for credit. Be sure to complete your "Payment," "Personal Certification Information," "Answers," and "Evaluation" forms. Your exam will be graded within 72 hours of receipt. Upon successful completion of the post-exam (70% or higher), a letter of completion will be mailed to the address provided.

### Online Completion Option:

Use this page to review the questions and mark your answers. Return to **dentalcetoday.com** and sign in. If you have not previously purchased the program, select it from the "Online Courses" listing and complete the online purchase process. Once purchased, the program will be added to your **User History** page where a **Take Exam** link will be provided directly across from the program title. Select the **Take Exam** link, complete all the program questions and **Submit** your answers. An immediate grade report will be provided. Upon receiving a passing grade, complete the online evaluation form. Upon submitting the form, your **Letter of Completion** will be provided immediately for printing.

### General Program Information:

Online users may log in to **dentalcetoday.com** any time in the future to access previously purchased programs and view or print letters of completion and results.

## POST EXAMINATION QUESTIONS

1. How many times greater a concentration of growth factors do platelet concentrates (platelet-rich plasma [PRP] and PRF) have in comparison to normal blood?
  - a. 2x to 3x.
  - b. 4x to 6x.
  - c. 6x to 8x.
  - d. 10x to 15x.
2. What is the difference between PRF and leukocyte-PRF (L-PRF)?
  - a. L-PRF contains more leukocytes.
  - b. L-PRF is the newer formulation with better biological properties.
  - c. L-PRF has more optimal centrifugation speeds.
  - d. Nothing; they are exactly the same.
3. Which of the following procedures can PRF be utilized for?
  - a. Socket healing.
  - b. Sinus lifting procedures.
  - c. Gingival recession.
  - d. All of the above.
4. What is the main difference between PRP and PRF?
  - a. PRP is more natural and therefore produces better results.
  - b. PRF does not contain anticoagulants, whereas PRP does.
  - c. PRP is a liquid, whereas PRF is the equivalent fibrin solution.
  - d. Nothing; they are exactly the same.
5. What are the main actions of PRF on human tissues?
  - a. Supplies angiogenic factors capable of improving blood flow to defect sites.
  - b. Contains a fibrin clot that acts as a 3-D provisional matrix.
  - c. Contains a number of defense-fighting immune cells.
  - d. All of the above.
6. What are the advantages of the low-speed centrifugation concept?
  - a. It reduces the number of leukocytes in the final PRF clot, thereby improving wound healing.
  - b. It improves bone graft stability by acting as a sticky matrix.
  - c. It allows a greater collection of leukocytes in the upper layer of PRF by reducing centrifugation g-force.
  - d. It is a new technique to prepare PRP from changes in the centrifugation protocols.
7. How long has PRF been shown to release growth factors to the surrounding microenvironment?
  - a. In the order of minutes.
  - b. In the order of hours.
  - c. One to 3 days.
  - d. 10 to 14 days.

## Basics of Platelet-Rich Fibrin Therapy

**8. What are the advantages of advanced-PRF (A-PRF) when compared to L-PRF?**

- a. Higher amount of growth factor release.
- b. Higher amount of collected leukocytes.
- c. Higher production of collagen from cells.
- d. All of the above.

**9. What is the centrifugation protocol to produce a liquid version of PRF (injectable PRF)?**

- a. 700 rpm for 3 minutes.
- b. 700 rpm for 8 minutes.
- c. 1,300 rpm for 3 minutes
- d. 1,300 rpm for 8 minutes.

**10. What is/are the primary role(s) of macrophages and leukocytes contained within PRF?**

- a. Secretion of a wide range of growth factors.
- b. Tissue wound healing.
- c. New blood vessel formation.
- d. All of the above.



# Basics of Platelet-Rich Fibrin Therapy

## PROGRAM COMPLETION INFORMATION

If you wish to purchase and complete this activity traditionally (mail or fax) rather than online, you must provide the information requested below. Please be sure to select your answers carefully and complete the evaluation information. To receive credit you must answer at least 7 of the 10 questions correctly.

**Complete online at:** [dentalcetoday.com](http://dentalcetoday.com)

## TRADITIONAL COMPLETION INFORMATION:

Mail or fax this completed form with payment to:

**Dentistry Today**

**Department of Continuing Education**

**100 Passaic Avenue**

**Fairfield, NJ 07004**

**Fax: 973-882-3622**

## PAYMENT & CREDIT INFORMATION:

Examination Fee: \$40.00 Credit Hours: 2.0

Note: There is a \$10 surcharge to process a check drawn on any bank other than a US bank. Should you have additional questions, please contact us at (973) 882-4700.

☐ I have enclosed a check or money order.

☐ I am using a credit card.

My credit card information is provided below.

☐ American Express ☐ Visa ☐ MC ☐ Discover

Please provide the following (please print clearly):

\_\_\_\_\_  
Exact Name on Credit Card

\_\_\_\_\_  
Credit Card #

\_\_\_\_\_  
Expiration Date

\_\_\_\_\_  
Signature



Approved PACE Program  
Provider FAGD/MAGD Credit  
Approval does not imply  
acceptance by a state or  
provincial board of dentistry  
or AGD endorsement.  
June 1, 2015 to  
May 31, 2018 AGD PACE  
approval number: 309062

**ADA CERP**® | Continuing Education  
Recognition Program

Dentistry Today, Inc. is an ADA CERP Recognized Provider.  
ADA CERP is a service of the American Dental Association to  
assist dental professionals in identifying quality providers of  
continuing dental education. ADA CERP does not approve or  
endorse individual courses or instructors, nor does it imply  
acceptance of credit hours by boards of dentistry. Concerns  
or complaints about a CE provider may be directed to the  
provider or to ADA CERP at  
[ada.org/goto/cerp](http://ada.org/goto/cerp).

## PERSONAL CERTIFICATION INFORMATION:

\_\_\_\_\_  
Last Name (PLEASE PRINT CLEARLY OR TYPE)

\_\_\_\_\_  
First Name

\_\_\_\_\_  
Profession / Credentials License Number

\_\_\_\_\_  
Street Address

\_\_\_\_\_  
Suite or Apartment Number

\_\_\_\_\_  
City

\_\_\_\_\_  
State

\_\_\_\_\_  
Zip Code

\_\_\_\_\_  
Daytime Telephone Number With Area Code

\_\_\_\_\_  
Fax Number With Area Code

\_\_\_\_\_  
E-mail Address

## ANSWER FORM: COURSE #: 208

Please check the correct box for each question below.

- |  |   |
|--|---|
| 1. <input type="checkbox"/> a <input type="checkbox"/> b <input type="checkbox"/> c <input type="checkbox"/> d | 6. <input type="checkbox"/> a <input type="checkbox"/> b <input type="checkbox"/> c <input type="checkbox"/> d  |
| 2. <input type="checkbox"/> a <input type="checkbox"/> b <input type="checkbox"/> c <input type="checkbox"/> d | 7. <input type="checkbox"/> a <input type="checkbox"/> b <input type="checkbox"/> c <input type="checkbox"/> d  |
| 3. <input type="checkbox"/> a <input type="checkbox"/> b <input type="checkbox"/> c <input type="checkbox"/> d | 8. <input type="checkbox"/> a <input type="checkbox"/> b <input type="checkbox"/> c <input type="checkbox"/> d  |
| 4. <input type="checkbox"/> a <input type="checkbox"/> b <input type="checkbox"/> c <input type="checkbox"/> d | 9. <input type="checkbox"/> a <input type="checkbox"/> b <input type="checkbox"/> c <input type="checkbox"/> d  |
| 5. <input type="checkbox"/> a <input type="checkbox"/> b <input type="checkbox"/> c <input type="checkbox"/> d | 10. <input type="checkbox"/> a <input type="checkbox"/> b <input type="checkbox"/> c <input type="checkbox"/> d |

## PROGRAM EVALUATION FORM

Please complete the following activity evaluation questions.

Rating Scale: Excellent = 5 and Poor = 0

Course objectives were achieved. \_\_\_\_\_

Content was useful and benefited your clinical practice. \_\_\_\_\_

Review questions were clear and relevant to the editorial. \_\_\_\_\_

Illustrations and photographs were clear and relevant. \_\_\_\_\_

Written presentation was informative and concise. \_\_\_\_\_

How much time did you spend reading the activity and  
completing the test? \_\_\_\_\_

What aspect of this course was most helpful and why? \_\_\_\_\_

What topics interest you for future *Dentistry Today* CE courses? \_\_\_\_\_